Your browser doesn't support javascript.
loading
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi, Sara Elena; Signori, Alessio; Stellato, Marco; Santini, Daniele; Maruzzo, Marco; De Giorgi, Ugo; Pedrazzoli, Paolo; Galli, Luca; Zucali, Paolo Andrea; Fantinel, Emanuela; Carella, Claudia; Procopio, Giuseppe; Milella, Michele; Boccardo, Francesco; Fratino, Lucia; Sabbatini, Roberto; Ricotta, Riccardo; Panni, Stefano; Massari, Francesco; Sorarù, Mariella; Santoni, Matteo; Cortellini, Alessio; Prati, Veronica; Soto Parra, Hector Josè; Atzori, Francesco; Di Napoli, Marilena; Caffo, Orazio; Messina, Marco; Morelli, Franco; Prati, Giuseppe; Nolè, Franco; Vignani, Francesca; Cavo, Alessia; Roviello, Giandomenico; Llaja Obispo, Miguel Angel; Porta, Camillo; Buti, Sebastiano; Fornarini, Giuseppe; Banna, Giuseppe Luigi.
Affiliation
  • Rebuzzi SE; Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.
  • Signori A; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy.
  • Stellato M; Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy.
  • Santini D; SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Maruzzo M; Department of Medical Oncology, Università Campus Bio-Medico of Roma, Rome, Italy.
  • De Giorgi U; Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Pedrazzoli P; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Galli L; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
  • Zucali PA; Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
  • Fantinel E; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Carella C; Department of Biomedical Sciences, Humanitas University, Milano, Italy.
  • Procopio G; Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Milano, Italy.
  • Milella M; Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
  • Boccardo F; Division of Medical Oncology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Fratino L; SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Sabbatini R; Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
  • Ricotta R; Academic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
  • Panni S; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, Italy.
  • Massari F; Medical Oncology Unit, Department of Oncology and Hemathology, University Hospital of Modena, Modena, Italy.
  • Sorarù M; Oncology Unit, IRCCS MultiMedica, Milan, Italy.
  • Santoni M; Medical Oncology Unit, ASSTl- Istituti Ospitalieri Cremona Hospital, Cremona, Italy.
  • Cortellini A; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Prati V; Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.
  • Soto Parra HJ; U. O. Oncologia, Ospedale di Camposampiero, Padova, Italy.
  • Atzori F; Oncology Unit, Macerata Hospital, Macerata, Italy.
  • Di Napoli M; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom.
  • Caffo O; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Messina M; Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno, Italy.
  • Morelli F; Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Italy.
  • Prati G; Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy.
  • Nolè F; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
  • Vignani F; Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
  • Cavo A; UOC Oncologia Medica, Istituto Fondazione G. Giglio, Cefalù, Italy.
  • Roviello G; Oncology Department, Gemelli Molise, Campobasso, Italy.
  • Llaja Obispo MA; Department of Oncology and Advanced Technologies AUSL - IRCCS, Reggio Emilia, Italy.
  • Porta C; Medical Oncology Division of Urogenital and Head and Neck Tumors, IEO, European Institute of Oncology IRCCS, Milano, Italy.
  • Buti S; Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy.
  • Fornarini G; Oncology Unit, Villa Scassi Hospital, Genova, Italy.
  • Banna GL; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy.
Front Oncol ; 12: 955501, 2022.
Article de En | MEDLINE | ID: mdl-36212433
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Italie Pays de publication: Suisse
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Italie Pays de publication: Suisse